利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.012 秒)

    Compounds for treating and preventing cognitive diseases and depression and methods of making same
    6.
    发明授权
    Compounds for treating and preventing cognitive diseases and depression and methods of making same 失效
    用于治疗和预防认知疾病和抑郁症的化合物及其制备方法

    公开(公告)号：US5204482A

    公开(公告)日：1993-04-20

    申请号：US650320

    申请日：1991-02-04

    申请人： Walter Gassner ,  Rene Imhof

    发明人： Walter Gassner ,  Rene Imhof

    IPC分类号： C07D231/14 ,  C07D261/18 ,  C07D263/34 ,  C07D277/56 ,  C07D413/04 ,  C07D417/04

    CPC分类号： C07D413/04 ,  C07D231/14 ,  C07D261/18 ,  C07D263/34 ,  C07D277/56 ,  C07D417/04

    摘要： Ethylenediamine monoamides of the formulaR--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2 Iwherein R is one of groups ##STR1## in which R.sup.1 is phenyl, monohalophenyl, monolower-alkylphenyl, monolower-alkoxyphenyl, monotrifluoromethylphenyl, monocyanophenyl or monaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R.sup.2 is hydrogen, halogen or amino, R.sup.3, R.sup.5 and R.sup.7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R.sup.4 and R.sup.6 each are hydrogen or amino and R.sup.8 is hydrogen or lower-alkyl,as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders.

    摘要翻译： 式R-CO-NH-CH2-CH2-NH2I的乙二胺单酰胺，其中R是基团之一，其中R1是苯基，单卤代苯基，单低级烷基苯基，单低级烷氧基苯基，单三氟甲基苯基，单氰基苯基或单芳基 - 低级烷氧基苯基，二卤代苯基，呋喃基，噻吩基或单卤噻吩基，R2是氢，卤素或氨基，R3，R5和R7各自为苯基，单卤代苯基，二卤代苯基，噻吩基，呋喃基或单卤代呋喃基，R4和R6各自为氢或氨基，R8为 氢或低级烷基，以及它们的药学上可用的酸加成盐。 该化合物具有低毒性的单胺氧化酶抑制性质，可用于治疗抑郁状态和认知障碍。

    ANTIBODIES AGAINST HUMAN IL-12
    7.
    发明申请
    ANTIBODIES AGAINST HUMAN IL-12 有权
    抗体人类IL-12抗体

    公开(公告)号：US20140348847A1

    公开(公告)日：2014-11-27

    申请号：US14251779

    申请日：2014-04-14

    申请人： HOFFMAN-LAROCHE, INC.

    发明人： Maurice Kent Gately ,  David Howard Presky

    IPC分类号： C07K16/24 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.

    摘要翻译： 本发明涉及新型p75异二聚体特异性抗人IL-12抗体，其特征在于比已知的异二聚体特异性IL-12单克隆抗体具有更高的效力和更高的中和人IL-12生物活性的功效。 异源二聚体特异性抗体识别人IL-12p75异二聚体的一个或多个表位，但不与单独的p40亚基结合。 异二聚体特异性IL-12抗体以与用于中和人IL-12生物活性的效力相似的效力中和恒河猴IL-12的生物活性，从而使其成为用于恒河猴体内研究的有用的IL-12拮抗剂。

    Antibodies against human IL-12
    8.
    发明授权
    Antibodies against human IL-12 有权
    针对人IL-12的抗体

    公开(公告)号：US08716449B2

    公开(公告)日：2014-05-06

    申请号：US11185615

    申请日：2005-07-19

    申请人： Maurice Kent Gately ,  David Howard Presky

    发明人： Maurice Kent Gately ,  David Howard Presky

    IPC分类号： C07K16/00 ,  C12P21/08 ,  C07K1/00

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.

    摘要翻译： 本发明涉及新型p75异二聚体特异性抗人IL-12抗体，其特征在于比已知的异二聚体特异性IL-12单克隆抗体具有更高的效力和更高的中和人IL-12生物活性的功效。 异源二聚体特异性抗体识别人IL-12p75异二聚体的一个或多个表位，但不与单独的p40亚基结合。 异二聚体特异性IL-12抗体以与用于中和人IL-12生物活性的效力相似的效力中和恒河猴IL-12的生物活性，使得它们可用于在恒河猴中进行体内研究的IL-12拮抗剂。